This article is sponsored content brought to you by Cenversa.
Osteoarthritis and associated joint pain are major concerns in both dogs and humans, particularly in older individuals. This condition commonly leads to stiffness, reduced mobility, and a noticeable decline in quality of life. Up to a third of dogs exhibit osteoarthritis-related symptoms, and drug treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used. Many veterinarians recommend the lowest effective NSAID dose due to potential side effects. Nutritional interventions, including marine omega-3 fatty acids, are often used alongside NSAIDs to support joint health while minimising drug exposure and associated risks. In some situations, well-designed nutritional strategies can provide sufficient relief on their own, avoiding drug-related side effects.
The benefits of marine omega-3 and greenshell mussel extract
Marine omega-3 fatty acids—particularly EPA and DHA from sources such as greenshell mussel—help modulate inflammatory pathways differently from NSAIDs and reduce ongoing low-grade inflammation within joints. These fatty acids convert into anti-inflammatory mediators such as series-3 prostaglandins, series-5 leukotrienes, and newly described pro-resolving mediators, all of which assist the body in suppressing and resolving inflammation. EPA and DHA are incorporated into phospholipid cell membranes in place of pro-inflammatory omega-6 fatty acids such as arachidonic acid (AA). This reduces the availability of AA as a precursor to inflammatory mediators, supporting a healthier inflammatory balance.
What is the best omega-3 source for osteoarthritis?
Fish oil is the most extensively studied omega-3 source for both canine and human osteoarthritis, primarily providing EPA and DHA in triglyceride form. More recently, krill oil and greenshell mussel oil have gained interest. Krill oil contains EPA and DHA largely bound to phospholipids rather than triglycerides, and some research suggests phospholipid-bound omega-3s may offer higher short-term bioavailability, although long-term advantages remain unclear.
Greenshell mussel naturally contains EPA and DHA in both triglyceride and phospholipid forms, making it a strong candidate for effective omega-3 delivery. However, commercial extracts vary significantly, and some provide only triglyceride forms, potentially reducing any bioavailability advantages. Multiple recent clinical studies have shown positive results for greenshell mussel oil beyond what would be expected from EPA and DHA alone. This may be due to the presence of eicosatetraenoic acid (ETA), a rare omega-3 fatty acid with potent effects in inflammatory joint conditions. ETA can inhibit both cyclooxygenase (COX) and lipoxygenase (LOX) pathways and strongly competes with 5-lipoxygenase, reducing leukotriene production and helping alleviate persistent inflammation within synovial tissues. For these reasons, greenshell mussel lipids are an important inclusion in nutritional joint-support formulations for dogs.
How important are supporting ingredients?
Nutritional formulations should be optimised for both stability and efficacy. Antioxidants such as lipid-soluble vitamin E help stabilise omega-3 fatty acids and may offer additional anti-inflammatory benefits. Plant-derived alphalinolenic acid can convert to EPA in dogs, contributing to anti-inflammatory processes. Gammalinolenic acid (GLA), an omega-6 fatty acid with anti-inflammatory properties, has demonstrated clinical benefits in reducing stiffness and improving mobility. These supporting ingredients can provide complementary and synergistic effects when combined with high-quality marine lipids.
Conclusion
Nutritional interventions can be used alone or alongside drug treatments; however, their effectiveness relies heavily on the omega-3 source and the overall formulation quality. For best outcomes, individual commercial products should be carefully assessed and validated.
Visit Cenversa
